Site map | Clozaril Connect

This website is owned and managed by Viatris. This website is intended for UK healthcare professionals only.

The active ingredient and instructions for use are the same for Clozaril® and Clozapine Mylan. Any mention of Clozaril® would also apply to Clozapine Mylan. Clozaril® is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics.

Treatment resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotic agents, including an atypical antipsychotic agent, prescribed for an adequate duration. Clozaril® is also indicated in psychotic disorders occurring during the course of Parkinson’s disease, in cases where standard treatment has failed.

© Copyright 2025 Viatris Inc. All rights reserved.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to CPMS@Viatris.com